AIIMS doctors in process of developing low cost adaptive cellular therapy for treatment of multiple myeloma
According to latest data from National cancer registry, the estimated number of incident cases of cancer in India in 2022 was ...
Aiims in process of making low cost therapy for treating multiple myeloma
Doctors at AIIMS, Delhi are in the process of developing a low cost antibody-based adaptive cellular therapy for treatment of ...
devdiscourse2h
AIIMS Innovates Affordable Antibody-Based Cancer Therapy
Doctors at AIIMS, Delhi are developing a low-cost, antibody-based adaptive cellular therapy targeting multiple myeloma, a ...
GEN1d
Flu Vaccine Response Boosted by Coupling Antigens from Multiple Subtypes
Novel vaccine platform improved protection against diverse influenza subtypes when tested in animal models and human ...
EurekAlert!1d
Stanford Medicine scientists design workaround that improves response to flu vaccine
Stitching together four molecules found in the standard flu vaccine ensures an immune response to all of them, Stanford Medicine scientists have shown.
News Medical2d
Breakthrough in antigen recognition: TRACeR-I enhances immune targeting
The TRACeR I platform was incorporated into a humanized antibody fragment in a bispecific T-cell engager (BiTE) format. When ...
Scientific Research Publishing2d
Analysis of HTLV Infection Status among Voluntary Blood Donors in Yulin City ()
Objective: To comprehensively understand the infection status of human T-lymphotropic virus (HTLV) among the voluntary blood ...
Reactive cysteines on peptide antigens may unlock new cancer immunotherapy possibilities
Northwestern Medicine scientists have developed a method for identifying reactive cysteines on peptide antigens within the ...
Novel bioluminescent immunosensor shows promise for quantitative point-of-care testing
A novel nanobody-based immunosensor, designed to function stably in undiluted biological fluids and harsh conditions, has ...
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and ...
BioWorld4d
Janssen presents first-in-class bispecific Vδ2 T-cell engaging antibody
The lack of acute myeloid leukemia-specific antigens is one of the challenges for targeted immunotherapy together with on-target off-tumor toxicities due to the expression of the target in normal ...